Stockscreener 앱 받기
128.63
0.69%
-0.90
시간 외 거래:
128.63
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella reports 2025 results, advances QTORIN drug pipeline - MSN
Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart
Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget
Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com
Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks
Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative
Form 8-KCurrent report - ADVFN
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Palvella appoints McDonough as SVP of market access, patient services - MSN
PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo
Palvella Publishes Review on Lymphatic Malformations in Medical Journal - MyChesCo
Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales - citybiz
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness - TipRanks
Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales to Drive QTORIN™ Launch for Rare Skin Disease - Quiver Quantitative
Palvella posts corporate presentation highlighting positive Phase 3 SELVA data and NDA plans - TradingView — Track All Markets
Palvella (NASDAQ: PVLA) shows pivotal rare-disease data and $274M cash runway - Stock Titan
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - GlobeNewswire
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN
Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo
Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
HC Wainwright Brokers Decrease Earnings Estimates for PVLA - MarketBeat
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - MarketBeat
What is HC Wainwright's Estimate for PVLA Q1 Earnings? - marketbeat.com
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Palvella’s Phase III Success And Fast Track Status Test Current Valuation - Yahoo Finance
Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada
Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - marketscreener.com
Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India
US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm
Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - MarketBeat
Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks
Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada
Oppenheimer raises Palvella Therapeutics price target on valuation - investing.com
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies - Minichart
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
2.69%
0.25%
자본화:
|
볼륨(24시간):